[A19-28] Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V

Last updated 01.07.2019

Project no.:

Commission awarded on 29.03.2019 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Head and nerves


Prophylaxis of migraine in adults who have at least 4 migraine days per month

Result of dossier assessment:

Added benefit not proven for 2 of 3 research questions due to lack of study data. Adults with episodic or chronic migraine for whom otherwise best supportive care is the only option: indication of major added benefit.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2019-09-19 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form